What is the Medicamen Biotech Ltd share price today?

The share price of NSE:MEDICAMEQ-BE on 01 Oct 2026 (as of 15:04:15 IST) is ₹317.9.

What is the NSE:MEDICAMEQ-BE 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:MEDICAMEQ-BE 52 week high low range shows a high of ₹447.65 and a low of ₹212.4.

What is the Medicamen Biotech Ltd market cap?

As on 01 Oct 2026, Medicamen Biotech Ltd market cap is ₹4431650000.

What is the shareholding pattern of Medicamen Biotech Ltd Stock?

The shareholding pattern of Medicamen Biotech Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 40.46% Foreign Institutional Investors (FII): 0.07% Domestic Institutional Investors (DII): 0.4% Mutual Funds: 0% Retail & Others: 59.07% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Medicamen Biotech Ltd?

The Price-to-Earnings (PE) ratio of Medicamen Biotech Ltd is 40.9239, and the Price-to-Book (PB) ratio is 2.9692, as on 01 Oct 2026.

Medicamen Biotech Share Price

262.15+2.05 (+0.79%)

-30.34% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+0.79%

1 Week

-1.80%

1 Month

-17.72%

3 Month

+7.83%

6 Month

-10.91%

YTD

-28.11%

1 Year

-30.34%

5 Year

-55.75%

10 Year

Max

-52.52%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

247.10

215.00

212.40

High

265.00

274.00

319.90

363.90

447.65

About

Medicamen Biotech Limited is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. It is a manufacturer and supplier of a range of products such as Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

LAURUSLABSNSE

ZYDUSLIFENSE

DRREDDYNSE

CIPLANSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

MEDICAMEQ-BENSE

LTP

1W Low

1W High

Market cap (₹)

1769.9+8.9 (0.51%)

1722

1855

4,24,202Cr

10064+400 (4.14%)

9621.50

10064

2,64,141Cr

4650+70 (1.53%)

4532

4675

1,74,402Cr

2323+79 (3.52%)

2206.10

2441.90

1,26,811Cr

1240.6+56.2 (4.75%)

1182

1254.20

1,23,685Cr

1368.3+23.3 (1.73%)

1336.70

1368.30

1,11,868Cr

1396.9+38.9 (2.86%)

1357

1396.90

1,11,650Cr

2475+5.7 (0.23%)

2457.90

2528

1,02,196Cr

1694.5+34.6 (2.08%)

1647.20

1697.40

96,951Cr

2015.9+26 (1.31%)

1974

2033.80

91,301Cr

265-1.95 (-0.73%)

247.10

274

372Cr

Medicamen Biotech Share Price

262.15+2.05 (+0.79%)

-30.34% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years12%

3 years12%

Last year22%

Compounded Profit Growth

10 years-

5 years-4%

3 years-13%

Last year49%

Stock Price CAGR

10 years-

5 years-15%

3 years-26%

1 year-31%

Return on Equity

10 years9%

5 years7%

3 years4%

Last year4%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	12%	12%	22%
-	-4%	-13%	49%
-	-15%	-26%	-31%
9%	7%	4%	4%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

LAURUSLABS

ZYDUSLIFE

DRREDDY

CIPLA

MANKIND

AUROPHARMA

LUPIN

MEDICAMEQ-BE

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,769.9	₹424202 Cr	38.68	8.29	58.23	₹11479 Cr
10,064	₹264141 Cr	90.3	34.04	128.41	₹2568 Cr
4,650	₹174402 Cr	82.11	14.04	106.21	₹2163 Cr
2,323	₹126811 Cr	94.64	8.17	33.94	₹889 Cr
1,240.6	₹123685 Cr	27.41	9.42	62.53	₹5040 Cr
1,368.3	₹111868 Cr	39.95	11.08	59.2	₹4196 Cr
1,396.9	₹111650 Cr	38.54	10.86	52.6	₹3879 Cr
2,475	₹102196 Cr	45.57	17.23	76.26	₹1913 Cr
1,694.5	₹96951 Cr	26.11	17.95	96.84	₹3505 Cr
2,015.9	₹91301 Cr	16.51	30.95	154.35	₹5333 Cr
265	₹372 Cr	34.32	1.56	12.82	₹10 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Mar 2019
₹48 Cr	₹61 Cr	₹47 Cr	₹47 Cr	₹43 Cr	₹30 Cr	₹45 Cr	₹45 Cr	₹43 Cr	₹47 Cr	₹47 Cr	₹44 Cr	₹42 Cr	₹39 Cr	₹36 Cr	₹34 Cr	₹33 Cr	₹23 Cr	₹33 Cr	₹33 Cr	₹28 Cr	₹21 Cr	₹33 Cr	₹31 Cr	₹28 Cr	₹24 Cr	₹35 Cr	₹36 Cr	₹31 Cr	₹24 Cr
₹86 L	₹2 Cr	₹54 L	₹37 L	₹47 L	₹5 Cr	₹14 L	₹29 L	₹59 L	₹57 L	₹83 L	₹55 L	₹38 L	₹35 L	₹63 L	₹53 L	₹96 L	₹34 L	₹83 L	₹48 L	₹8 L	₹54 L	₹10,000	₹13 L	₹8 L	₹1 Cr	₹45 L	₹35 L	₹4 L	₹7 L
₹49 Cr	₹62 Cr	₹47 Cr	₹48 Cr	₹44 Cr	₹35 Cr	₹45 Cr	₹45 Cr	₹44 Cr	₹48 Cr	₹47 Cr	₹44 Cr	₹42 Cr	₹39 Cr	₹36 Cr	₹34 Cr	₹34 Cr	₹23 Cr	₹33 Cr	₹33 Cr	₹28 Cr	₹22 Cr	₹33 Cr	₹31 Cr	₹28 Cr	₹25 Cr	₹36 Cr	₹36 Cr	₹31 Cr	₹24 Cr
₹45 Cr	₹57 Cr	₹44 Cr	₹44 Cr	₹40 Cr	₹32 Cr	₹41 Cr	₹42 Cr	₹41 Cr	₹43 Cr	₹43 Cr	₹41 Cr	₹37 Cr	₹34 Cr	₹31 Cr	₹29 Cr	₹29 Cr	₹19 Cr	₹28 Cr	₹28 Cr	₹23 Cr	₹17 Cr	₹28 Cr	₹26 Cr	₹24 Cr	₹21 Cr	₹31 Cr	₹30 Cr	₹27 Cr	₹20 Cr
₹5 Cr	₹7 Cr	₹5 Cr	₹6 Cr	₹5 Cr	₹4 Cr	₹7 Cr	₹6 Cr	₹4 Cr	₹6 Cr	₹6 Cr	₹5 Cr	₹7 Cr	₹7 Cr	₹7 Cr	₹6 Cr	₹7 Cr	₹5 Cr	₹7 Cr	₹7 Cr	₹6 Cr	₹5 Cr	₹5 Cr	₹6 Cr	₹4 Cr	₹4 Cr	₹6 Cr	₹6 Cr	₹5 Cr	₹4 Cr
₹83 L	₹38 L	₹97 L	₹99 L	₹1 Cr	₹65 L	₹76 L	₹1 Cr	₹71 L	₹2 Cr	₹65 L	₹91 L	₹96 L	₹86 L	₹68 L	₹62 L	₹77 L	₹56 L	₹49 L	₹30 L	₹4 L	₹36 L	₹9 L	₹38 L	₹24 L	₹0	₹19 L	₹21 L	₹16 L	₹20 L
₹3 Cr	₹5 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹4 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹5 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹5 Cr	₹5 Cr	₹5 Cr	₹4 Cr	₹4 Cr	₹5 Cr	₹3 Cr	₹3 Cr	₹5 Cr	₹5 Cr	₹4 Cr	₹4 Cr
₹2 Cr	₹4 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹91 L	₹80 L	₹2 Cr	₹2 Cr	₹1 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹2 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Miscellaneous Expenses not written off

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
—	—	—	—	—	—	—	—
₹14 Cr	₹13 Cr	₹13 Cr	₹13 Cr	₹12 Cr	₹12 Cr	₹12 Cr	₹12 Cr
₹9 Cr	₹0	₹0	₹3 Cr	₹0	₹0	₹0	₹0
₹251 Cr	₹199 Cr	₹194 Cr	₹178 Cr	₹134 Cr	₹121 Cr	₹109 Cr	₹75 Cr
₹251 Cr	₹199 Cr	₹194 Cr	₹178 Cr	₹134 Cr	₹121 Cr	₹109 Cr	₹75 Cr
₹273 Cr	₹212 Cr	₹207 Cr	₹193 Cr	₹146 Cr	₹133 Cr	₹121 Cr	₹87 Cr
₹3 Cr	₹1 Cr	₹0	₹0	₹0	₹0	₹0	₹0
₹3 Cr	₹4 Cr	₹1 Cr	₹87 L	₹5 Cr	₹6 Cr	₹2 Cr	₹2 L
₹3 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0
-₹3 Cr	-₹3 Cr	-₹3 Cr	-₹2 Cr	-₹50 L	₹28 L	₹16 L	₹41 L
₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹98 L
₹5 Cr	₹3 Cr	₹50 L	₹65 L	₹6 Cr	₹8 Cr	₹4 Cr	₹1 Cr
—	—	—	—	—	—	—	—
₹40 Cr	₹43 Cr	₹39 Cr	₹48 Cr	₹43 Cr	₹32 Cr	₹37 Cr	₹31 Cr
₹2 Cr	₹1 Cr	₹11 Cr	₹7 Cr	₹5 Cr	₹5 Cr	₹6 Cr	₹78 L
₹42 Cr	₹30 Cr	₹30 Cr	₹23 Cr	₹19 Cr	₹11 Cr	₹8 Cr	₹12 Cr
₹4 Cr	₹5 Cr	₹5 Cr	₹4 Cr	₹5 Cr	₹5 Cr	₹6 Cr	₹6 Cr
₹88 Cr	₹78 Cr	₹85 Cr	₹83 Cr	₹73 Cr	₹53 Cr	₹56 Cr	₹49 Cr
₹369 Cr	₹294 Cr	₹292 Cr	₹277 Cr	₹225 Cr	₹194 Cr	₹181 Cr	₹137 Cr
₹49 Cr	₹34 Cr	₹31 Cr	₹26 Cr	₹26 Cr	₹19 Cr	₹11 Cr	₹12 Cr
—	—	—	—	—	—	—	—
₹144 Cr	₹139 Cr	₹137 Cr	₹130 Cr	₹124 Cr	₹116 Cr	₹58 Cr	₹47 Cr
₹59 Cr	₹52 Cr	₹45 Cr	₹38 Cr	₹32 Cr	₹26 Cr	₹24 Cr	₹22 Cr
₹85 Cr	₹87 Cr	₹92 Cr	₹93 Cr	₹92 Cr	₹90 Cr	₹34 Cr	₹24 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹40 Cr	₹15 Cr
₹5 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹87 L	₹78 L	₹63 L	₹58 L
₹49 Cr	₹35 Cr	₹33 Cr	₹12 Cr	₹1 Cr	₹90 L	₹29 L	₹29 L
₹138 Cr	₹123 Cr	₹126 Cr	₹106 Cr	₹94 Cr	₹91 Cr	₹75 Cr	₹40 Cr
—	—	—	—	—	—	—	—
₹70 Cr	₹62 Cr	₹59 Cr	₹45 Cr	₹27 Cr	₹5 Cr	₹17 Cr	₹15 Cr
₹82 Cr	₹69 Cr	₹55 Cr	₹65 Cr	₹63 Cr	₹53 Cr	₹50 Cr	₹43 Cr
₹31 Cr	₹4 Cr	₹15 Cr	₹21 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹9 Cr
₹2 Cr	₹3 Cr	₹2 Cr	₹3 Cr	₹20 Cr	₹23 Cr	₹22 Cr	₹15 Cr
₹39 Cr	₹27 Cr	₹28 Cr	₹30 Cr	₹9 Cr	₹11 Cr	₹13 Cr	₹14 Cr
₹224 Cr	₹165 Cr	₹160 Cr	₹163 Cr	₹123 Cr	₹96 Cr	₹104 Cr	₹96 Cr
₹136 Cr	₹86 Cr	₹75 Cr	₹81 Cr	₹50 Cr	₹43 Cr	₹48 Cr	₹48 Cr
₹7 Cr	₹7 Cr	₹7 Cr	₹7 Cr	₹8 Cr	₹7 Cr	₹2 Cr	₹42 L
₹369 Cr	₹294 Cr	₹292 Cr	₹277 Cr	₹225 Cr	₹194 Cr	₹181 Cr	₹137 Cr
₹190	₹161	₹158	₹145	₹114	₹103	₹98	₹74
₹190	₹161	₹158	₹145	₹114	₹103	₹98	₹74

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
₹12 Cr	₹10 Cr	₹13 Cr	₹17 Cr	₹18 Cr	₹16 Cr	₹18 Cr	₹17 Cr
₹9 Cr	₹10 Cr	₹11 Cr	₹9 Cr	₹7 Cr	₹3 Cr	₹3 Cr	₹2 Cr
-₹52 Cr	-₹26 Cr	-₹28 Cr	-₹29 Cr	-₹18 Cr	-₹3 Cr	-₹4 Cr	-₹11 Cr
-₹31 Cr	-₹7 Cr	-₹4 Cr	-₹3 Cr	₹7 Cr	₹17 Cr	₹17 Cr	₹8 Cr
-₹33 Cr	-₹8 Cr	-₹7 Cr	-₹6 Cr	₹4 Cr	₹13 Cr	₹13 Cr	₹4 Cr
-₹3 Cr	-₹1 Cr	-₹6 Cr	-₹6 Cr	-₹8 Cr	-₹18 Cr	-₹37 Cr	-₹15 Cr
₹64 Cr	-₹1 Cr	₹6 Cr	₹29 Cr	₹4 Cr	₹6 Cr	₹19 Cr	-₹4 Cr
₹28 Cr	-₹11 Cr	-₹6 Cr	₹17 Cr	-₹7 L	₹80 L	-₹5 Cr	-₹14 Cr
₹4 Cr	₹15 Cr	₹21 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹9 Cr	₹23 Cr
₹31 Cr	₹4 Cr	₹15 Cr	₹21 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹9 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Medicamen Biotech Share Price

262.15+2.05 (+0.79%)

-30.34% past 1 Year

Shareholding summary

Promoters

40.46%

FII

DII

Others

59.54%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
40.46%	40.46%	40.46%	40.46%	40.46%	40.46%
0.00%	0.07%	0.10%	0.02%	0.05%	0.00%
0.00%	0.40%	0.00%	0.44%	0.59%	0.64%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
59.54%	59.07%	59.44%	59.08%	58.90%	58.90%

Bulk & block deals

Name

Shivalik Rasayan Limited

Growel Remedies Limited

Jmp Securities Pvt Ltd

Medicamen Canada Inc

Visionstar

Bp Fintrade Private Limited

Geometric Securities & Advisory P Ltd

Rajasthan Global Securities Private Limited

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
22 Mar 2024	Purchase	8.44 Cr	₹421.86	2 L	Bulk	1.474426	NSE
22 Mar 2024	Sell	8.44 Cr	₹421.86	2 L	Bulk	1.474426	NSE
16 Nov 2016	Sell	1.36 Cr	₹252.11	53.81 K	Bulk	0.396702	BSE
16 Nov 2016	Purchase	1.38 Cr	₹250.96	55.01 K	Bulk	0.405548	BSE
01 Mar 2016	Sell	61.71 L	₹44.08	1.40 L	Bulk	1.032098	BSE
07 Jan 2016	Purchase	38.26 L	₹76.51	50 K	Bulk	0.368607	BSE
07 Jan 2016	Purchase	17.02 L	₹77.30	22.01 K	Bulk	0.162275	BSE
07 Jan 2016	Sell	40.19 L	₹76.83	52.31 K	Bulk	0.385607	BSE
16 Nov 2015	Sell	18.27 L	₹35.70	51.19 K	Bulk	0.377379	BSE
16 Nov 2015	Purchase	17.31 L	₹35.70	48.50 K	Bulk	0.357534	BSE

Insider trading & SAST

Client name

Sanjay Bansal

Shivalik Rasayan Ltd & Pacs

Shivalik Rasayan Limited

Geetika Madan

Growel Remedies Ltd

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
30 Sep 2026	Director	Disposal	0.241902	0.51	1.05 Cr	₹321.29	32.81 K	28 Sep 2026 - 30 Sep 2026	Market Sale	70,000	Insider Trading	—	Equity
24 Sep 2025	Director	Disposal	0.737213	0.76	0	—	1 L	23 Sep 2025	Gift	1,02,813	Insider Trading	—	Equity Shares
07 May 2025	Promoter	Acquisition	0.15	40.46	0	—	21 K	21 Mar 2025 - 24 Apr 2025	Market	54,87,095	SAST	29(2)	—
22 Mar 2025	Promoter	Acquisition	0.165164	43.16	1.04 Cr	₹494.14	21 K	21 Mar 2025	Market Purchase	54,87,095	Insider Trading	—	Equity Shares
17 Dec 2024	Connected Person	Disposal	0.01573	0.19	11.45 L	₹572.29	2 K	12 Dec 2024	Market Sale	24,687	Insider Trading	—	Equity Shares
17 Dec 2024	Connected Person	Disposal	0.023595	0.21	13.46 L	₹448.65	3 K	25 Nov 2024	Market Sale	27,000	Insider Trading	—	Equity Shares
17 Dec 2024	Connected Person	Disposal	0.002462	0.21	1.92 L	₹612.17	313	06 Dec 2024	Market Sale	26,687	Insider Trading	—	Equity Shares
18 Sep 2024	Connected Person	Disposal	0.011719	0.23	7.09 L	₹475.86	1.49 K	16 Sep 2024	Market Sale	30,000	Insider Trading	—	Equity Shares
18 Sep 2024	Connected Person	Disposal	0.007865	0.24	3.98 L	₹398.20	1 K	20 Aug 2024	Market Sale	31,490	Insider Trading	—	Equity Shares
05 Apr 2024	Promoter	Disposal	1.57	—	0	—	2 L	22 Mar 2024	Market	—	SAST	29(2)	—

Medicamen Biotech Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Medicamen Biotech Share Price

Medicamen Biotech Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Medicamen Biotech Share Price

Medicamen Biotech Share Price

Oscillators

Moving averages

Medicamen Biotech Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Medicamen Biotech Share Price

Corporate Actions

Company details

Medicamen Biotech Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Medicamen Biotech Share Price

News

Medicamen Biotech - Quaterly Results

Medicamen Biotech reports Profit after tax of 2.97 Crores, in the March 2026 quarter

Medicamen Biotech informs about board meeting

Medicamen Biotech - Quaterly Results

Medicamen Biotech reports Profit after tax of 2.59 Crores, in the December 2025 quarter

Medicamen Biotech Q2 FY26 net profit dips marginally, revenue and EBITDA decline YoY.

Medicamen Biotech reports Profit after tax of 2.21 Crores, in the September 2025 quarter

Medicamen Biotech - Quaterly Results

Medicamen Biotech - Quaterly Results

Medicamen Biotech - Quaterly Results

Medicamen Biotech reports Profit after tax of 1.64 Crores, in the June 2025 quarter

Medicamen Biotech gets USFDA’s approval for Bortezomib for injection

Medicamen Biotech - Quaterly Results

Medicamen Biotech reports Profit after tax of 2.41 Crores, in the March 2025 quarter

Medicamen Biotech signs contract for CDMO with XGX pharma

Medicamen Biotech informs about closure of trading window

Medicamen Biotech informs about disclosure

Medicamen Biotech - Quaterly Results

Medicamen Biotech - Quaterly Results

Medicamen Biotech - Quaterly Results

Medicamen Biotech Ltd Share Price Today

Medicamen Biotech Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator